- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.12. | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.11. | Adial Pharmaceuticals raises $2.86 million through warrant exercise | 1 | Investing.com | ||
| 26.11. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds | 1 | GlobeNewswire (USA) | ||
| 14.11. | Adial Pharmaceuticals GAAP EPS of -$0.08 | 6 | Seeking Alpha | ||
| 14.11. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | 309 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 14.11. | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | ADIAL PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 17.10. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show | 1 | GlobeNewswire (USA) | ||
| ADIAL PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 09.10. | Adial completes key validation for alcohol disorder treatment test | 1 | Investing.com | ||
| 09.10. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution | 133 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 16.09. | Adial Pharmaceuticals Highlights Favorable Comments From FDA Meeting For Lead Program In Alcohol Use Disorder | 2 | Benzinga.com | ||
| 16.09. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04 | 268 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 16.09. | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.09. | ADIAL PHARMACEUTICALS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 03.09. | Adial Pharmaceuticals receives 180-day Nasdaq extension to meet $1 bid price | 1 | Investing.com | ||
| 03.09. | ADIAL PHARMACEUTICALS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.09. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule | 1 | GlobeNewswire (USA) | ||
| 20.08. | Adial Hails Senate Moves on Trials | 1 | Baystreet.ca | ||
| 20.08. | Adial Pharmaceuticals, Inc: Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments | 190 | GlobeNewswire (Europe) | GLEN ALLEN, Va., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies... ► Artikel lesen | |
| 14.08. | Adial Pharmaceuticals reports Q2 results | 1 | Seeking Alpha |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,388 | +3,10 % | Revolutionäre Fortschritte: BioTech-Ideen für 2026! Bayer, Novo Nordisk, BioNxt, Vidac, BioNTech und Evotec! | Trotz eines schwierigen Umfelds 2025 bleibt der Biotech-Sektor fundamental attraktiv, da der medizinische Fortschritt nicht zum Stillstand kommt. Der rasante Einsatz von Künstlicher Intelligenz und... ► Artikel lesen | |
| MEDIGENE | 0,025 | +16,67 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 38,985 | -0,35 % | QIAGEN N.V.: QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million | Return of approximately $500 million maximum approved by shareholders set to be completed on January 7, 2026 Capital return to be conducted through synthetic share repurchase combines a... ► Artikel lesen | |
| CUREVAC | 3,478 | +1,70 % | Sonntagsausblick: Curevac-Aktie vor spannender Handelswoche - Experten sind sich uneinig! | ||
| MODERNA | 27,580 | -9,19 % | Forget Moderna Stock, This is a Much Better Buy | ||
| VALNEVA | 3,654 | -1,77 % | Wochenend-Analyse: Valneva-Aktie vor entscheidender Woche - Montag könnte alles ändern! | ||
| NOVAVAX | 5,766 | -2,24 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| STRYKER | 301,70 | -0,59 % | Stryker Earnings Preview: What to Expect | ||
| BIOFRONTERA | 2,430 | +4,29 % | PTA-news: Biofrontera AG: Biofrontera berichtet über die Ergebnisse der ersten neun Monate des Jahres 2025 | DJ PTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DER ERSTEN NEUN MONATE DES JAHRES 2025
Unternehmensmitteilung für den Kapitalmarkt
Biofrontera AG: BIOFRONTERA... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,310 | -0,43 % | EQS-News: Heidelberg Pharma AG: Brief des Vorstandsvorsitzenden | EQS-News: Heidelberg Pharma AG
/ Schlagwort(e): Sonstiges
Heidelberg Pharma: Brief des Vorstandsvorsitzenden
17.12.2025 / 09:21 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 47,000 | -3,69 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112) in Autoimmune Diseases and Hematologic Malignancies | -Four autoimmune patients treated to date demonstrate deep B-cell depletion sustained for at least 28 days; initial efficacy data suggest significant clinical improvement in patients dosed at the... ► Artikel lesen | |
| CORE ONE LABS | - | - | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 22.09.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 22.09.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 22.09.2025ISIN NameAU000000PEK2 PEAK... ► Artikel lesen | |
| BIOXXMED | 0,026 | -1,92 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| OCUGEN | 1,259 | -0,12 % | Ocugen Provides Business Update with Third Quarter 2025 Financial Results | Phase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward 1H 2027 Biologics License Application (BLA) filing with 50% enrollment completed to date European Medicines Agency (EMA)... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 28,970 | -1,63 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen |
Das Unternehmen ADIAL PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,233 Euro und damit -2,88 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADIAL PHARMACEUTICALS INC finden Sie auf Wallstreet Online.